Acceptance by the U.S. Food and Drug Administration (FDA) of the IND Application for BP2202
BrightPath Biotherapeutics Co.,Ltd.
BP2202 (iPS cell-derived BCMA CAR-NKT cell therapy) and clinical trial sites in the United States
No impact on financial results for the fiscal year ending March 2027
No impact from this matter on financial results for the fiscal year ending March 2027
Related procedures
Acceptance of the IND application
U.S. Food and Drug Administration (FDA)
The company will establish the infrastructure for conducting the trial at clinical trial sites in the United States, and transfer the investigational drug, following completion of manufacturing and quality testing, from the CDMO to each trial site, with the aim of dosing the first patient within the year. The company aims to evaluate the safety and preliminary clinical activity of BP2202 and build a foundation for the further development of this platform technology.
| Item | Details |
|---|---|
| Event name | Acceptance by the U.S. Food and Drug Administration (FDA) of the IND Application for BP2202 |
| Subject Entity | BrightPath Biotherapeutics Co.,Ltd. |
| Target Locations / Products | BP2202 (iPS cell-derived BCMA CAR-NKT cell therapy) and clinical trial sites in the United States |
| Amount of Impact on Business Performance | No impact on financial results for the fiscal year ending March 2027 |
| Impact on Earnings Forecast | No impact from this matter on financial results for the fiscal year ending March 2027 |
| Type of litigation or proceeding | Acceptance of the IND application |
| Court or authority | U.S. Food and Drug Administration (FDA) |
| Outlook | The company will establish the infrastructure for conducting the trial at clinical trial sites in the United States, and transfer the investigational drug, following completion of manufacturing and quality testing, from the CDMO to each trial site, with the aim of dosing the first patient within the year. The company aims to evaluate the safety and preliminary clinical activity of BP2202 and build a foundation for the further development of this platform technology. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The FDA’s acceptance of the IND application makes it possible to initiate a Phase 1 clinical trial in the United States. The company considers this a major achievement in advancing its proprietary iPS cell-derived CAR-NKT cell platform into clinical development and an important research and development milestone.